Reviewing statin therapy in diabetes-Towards the best practise

Primary Care Diabetes

Volumn 4, Issue 1, 2010, Pages 9-15

  Matikainen, Niina ^a   Kahri, Juhani ^a   Taskinen, Marja Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiovascular disease; Diabetic dyslipidemia; Microvascular disease; Statin therapy; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VASCULOTROPIN;

ARTERY DISEASE; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MICROANGIOPATHY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; VASCULAR DISEASES;

EID: 77949292837     PISSN: 17519918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcd.2010.01.005     Document Type: Review

References (49)

1. The global challenge of diabetes. Lancet 371 (2008) 1723
2. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr. Mol. Med. 5 (2005) 297-308
3. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44 (2004) 720-732
5. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348 (2003) 383-393
6. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358 (2008) 580-591
7. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
8. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
9. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., Armitage J., and Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
10. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 32 (2009) S13-S61
11. Donnelly L.A., Doney A.S., Morris A.D., et al. Long-term adherence to statin treatment in diabetes. Diabet. Med. 25 (2008) 850-855
12. Laing S.P., Swerdlow A.J., Slater S.D., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46 (2003) 760-765
13. Skrivarhaug T., Bangstad H.J., Stene L.C., et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 49 (2006) 298-305
14. Margeirsdottir H.D., Larsen J.R., Brunborg C., et al. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 51 (2008) 554-561
15. Retnakaran R., and Zinman B. Type 1 diabetes, hyperglycaemia, and the heart. Lancet 371 (2008) 1790-1799 (see comment)
16. Young M.J., McCardle J.E., Randall L.E., and Barclay J.I. Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. Diabetes Care 31 (2008) 2143-2147
17. Wright R.J., and Frier B.M. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab. Res. Rev. 24 (2008) 353-363
18. Fried L.F., Forrest K.Y., Ellis D., et al. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J. Diabetes Complications 15 (2001) 113-119
19. Bloomgarden Z.T. Diabetic retinopathy and diabetic neuropathy. Diabetes Care 30 (2007) 760-765
20. Medina R.J., O'Neill C.L., Devine A.B., et al. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS ONE 3 (2008) e2584
21. Al-Shabrawey M., Bartoli M., El-Remessy A.B., et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 49 (2008) 3231-3238
22. Sen K., Misra A., Kumar A., and Pandey R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56 (2002) 1-11
23. Gupta A., Gupta V., Thapar S., and Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 137 (2004) 675-682
24. Zhang J., and McGwin Jr. G. Association of statin use with the risk of developing diabetic retinopathy. Arch. Ophthalmol. 125 (2007) 1096-1099
25. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
26. Chew E.Y., Ambrosius W.T., Howard L.T., et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am. J. Cardiol. 99 (2007) 103111-104111
27. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353 (2005) 238-248
28. Agarwal R. Effects of statins on renal function. Mayo Clin. Proc. 82 (2007) 1381-1390
29. Chan D.T., Irish A.B., Dogra G.K., and Watts G.F. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 196 (2008) 823-834
30. Athyros V.G., Kakafika A.I., Karagiannis A., and Mikhailidis D.P. Do we need to consider inflammatory markers when we treat atherosclerotic disease?. Atherosclerosis 200 (2008) 1-12
31. Davis T.M., Yeap B.B., Davis W.A., and Bruce D.G. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 51 (2008) 562-566
32. Oltman C.L., Davidson E.P., Coppey L.J., et al. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 16 (2008) 82-89
33. Ii M., Nishimura H., Kusano K.F., et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 112 (2005) 93-102
34. Fegan P.G., Shore A.C., Mawson D., et al. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med. 22 (2005) 1670-1676
35. Beishuizen E.D., Tamsma J.T., Jukema J.W., et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 28 (2005) 1668-1674
36. van Venrooij F.V., van de Ree M.A., Bots M.L., et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25 (2002) 1211-1216
37. Dogra G., Watts G., Chan D., and Stanton K. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet. Med. 22 (2005) 239-242
38. Mullen M.J., Wright D., Donald A.E., et al. Atorvastatin but not l-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J. Am. Coll. Cardiol. 36 (2000) 410-416
39. Janatuinen T., Knuuti J., Toikka J.O., et al. Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1303-1308
40. Brumeanu T.D., Goldstein R., and Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 119 (2006) 1-12
41. Jialal I., Miguelino E., Griffen S.C., and Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 92 (2007) 3136-3140
42. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24 (2001) 1335-1341
43. Armitage J. The safety of statins in clinical practice. Lancet 370 (2007) 1781-1790
44. SEARCH Collaborative G., Link E., Parish S., et al. N. Engl. J. Med. 359 (2008) 789-799
45. Pasanen M.K., Neuvonen M., Neuvonen P.J., and Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genom. 16 (2006) 873-879
46. Pasanen M.K., Fredrikson H., Neuvonen P.J., and Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82 (2007) 726-733
47. Niemi M., Pasanen M.K., and Neuvonen P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80 (2006) 356-366
48. Laaksonen R., Katajamaa M., Paiva H., et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 1 (2006) e97
49. ACCORD Study Group, Buse J.B., Bigger J.T., et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 99 (2007) 2133-33i